| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Malignant Mesothelioma | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Mesothelioma | |||||
| 3 | More general conditions related to this trial | ||||
| Adenoma | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms, Glandular and Epithelial | |||||
| Neoplasms, Mesothelial | |||||
| 4 | Interventions listed in this trial | ||||
| gefitinib | |||||
| 5 | More general drug interventions related to this trial | ||||
| Antineoplastic Agents | |||||
| Enzyme Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Protein Kinase Inhibitors | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| Cancer and Leukemia Group B | |||||
| National Cancer Institute (NCI) | |||||
|
